| (B) | ||||
|---|---|---|---|---|
| Variables | Univariable analysis | Multivariable analysis | ||
| HR (95% CI) | P | aHR (95% CI) | P | |
| Sex | ||||
| Male | Ref | |||
| Female | 0.93 (0.48–1.80) | 0.84 | ||
| Age, year | 0.97 (0.96–0.99) | 0.01 | 0.98 (0.96–1.00) | 0.09 |
| TARE-eligibility | ||||
| TARE-eligible | Ref | Ref | ||
| TARE-ineligible | 2.30 (1.28–4.11) | 0.01 | 2.16 (1.14–4.07) | 0.02 |
| Tumor size, cm | 1.06 (1.01–1.11) | 0.03 | 1.00 (0.91–1.09) | 0.93 |
| MoRAL | 1.0001 (0.9999–1.0003) | 0.35 | 0.9999 (0.9996–1.0003) | 0.75 |
| AST | 1.007 (1.003–1.011) | 0.001 | 1.006 (1.003–1.010) | 0.001 |
| ALT | 1.000 (0.996–1.004) | 1.00 | ||
| Child-Pugh class | ||||
| Class A | Ref | Ref | ||
| Class B | 1.98 (1.230–3.02) | 0.002 | 1.30 (0.70–2.42) | 0.40 |
| BCLC stage | ||||
| BCLC A | Ref | Ref | ||
| BCLC B | 1.76 (1.03–2.99) | 0.04 | 2.05 (1.28–3.27) | 0.003 |
| Platelet, x 1,000/mm3 | 1.001 (0.999–1.003) | 0.35 | ||
| LSF, % | 1.01 (0.99–1.04) | 0.30 | ||
AFP, alpha-fetoprotein; aHR, adjusted hazard ratio; ALT, alanine transferase; AST, aspartate transaminase; BCLC, Barcelona Clinic Liver Cancer; CI, confidence interval; HR, hazard ratio; IPTW, inverse probability of treatment weighting; LSF, lung shunt fraction; MoRAL, model to predict tumor recurrence after living donor transplantation; TARE, transarterial radioembolization.